The Diverse Distribution of Risk Factors between Breast Cancer Subtypes of ER, PR and HER2: A 10-Year Retrospective Multi-Center Study in China

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Song, Qingkun ^a   Huang, Rong ^b   Li, Jing ^a   Fan, Jinhu ^a   Zheng, Shan ^a   Zhang, Bin ^c   Yang, Hongjian ^d   Tang, Zhonghua ^e   He, Jianjun ^f   Xie, Xiaoming ^g   Li, Hui ^h   Li, Jiayuan ^b   Qiao, Youlin ^a  

^a CANCER HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

^c LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^d ZHEJIANG CANCER HOSPITAL   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

^f XI'AN JIAOTONG UNIVERSITY   (China)

^g SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^h SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BREAST CANCER; CANCER CLASSIFICATION; CELL DIFFERENTIATION; CHINA; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MAMMARY GLAND; MEDICAL RECORD; OBESITY; PARITY; POSTMENOPAUSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; BREAST NEOPLASMS; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREGNANCY; PREMENOPAUSE; PROGNOSIS; STATISTICAL MODEL;

ADULT; BODY MASS INDEX; BREAST NEOPLASMS; CHINA; FEMALE; GENE EXPRESSION; HUMANS; LOGISTIC MODELS; MIDDLE AGED; PARITY; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84882715261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072175     Document Type: Article

References (30)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C,et al. (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer. IARC Website. Available: http://globocan.iarc.fr. Accessed 2012 Dec 8.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R,et al. (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Betheda: National Cancer Institute. SEER Website. Available: http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 2012 Oct 09.
3. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global Cancer Statistics 2002. CA A Cancer Journal for Clinicians 55: 74-108.
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 295: 2492-2502.
5. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, et al. (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18: 2059-2069.
6. Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, et al. (2007) Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer 121: 1079-1085.
7. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, et al. (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103: 250-263.
8. Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, et al. (2010) Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res 12: R10.
9. Li J, Zhang BN, Fan JH, Pang Y, Zhang P, et al. (2011) A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer 11: 364.
10. Zheng S, Bai JQ, Li J, Fan JH, Pang Y, et al. (2012) The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years. Int J Cancer 131: 2622-2631.
11. Zarbo RJ, Hammond ME, (2003) Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 127: 549-553.
12. Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, et al. (2011) Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res 17: 753-758.
13. WHO Regional Office for the Western Pacific/International Association for the Study of Obesity/International Obesity Task Force (2000) The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia.
14. Dunnwald LK, Rossing MA, Li CI, (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9: R6.
15. Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, et al. (2010) Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori 96: 103-110.
16. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN, (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7: 4-13.
17. Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, et al. (2011) Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol 174: 661-671.
18. Devi CR, Tang TS, Corbex M, (2012) Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia. Int J Cancer 131: 2869-2877.
19. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, et al. (2009) Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 169: 1251-1259.
20. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, et al. (2012) Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 104: 1094-1101.
21. MacMahon B, (1993) General Motors Cancer Research Prizewinners Laureates Lectures. Charles S. Mott Prize. Reproduction and cancer of the breast. Cancer 71: 3185-3188.
22. Russo J, Tay LK, Russo IH, (1982) Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2: 5-73.
23. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, et al. (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13: 1558-1568.
24. Ponten J, Holmberg L, Trichopoulos D, Kallioniemi OP, Kvale G,et al. (1990) Biology and natural history of breast cancer. Int J Cancer Suppl 5: 5-21.
25. Ma H, Bernstein L, Pike MC, Ursin G, (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8: R43.
26. Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A, (2006) Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study. Int J Cancer 119: 1683-1689.
27. Iwasaki M, Otani T, Inoue M, Sasazuki S, Tsugane S, (2007) Body size and risk for breast cancer in relation to estrogen and progesterone receptor status in Japan. Ann Epidemiol 17: 304-312.
28. Wei S, Schmidt MD, Dwyer T, Norman RJ, Venn AJ, (2009) Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring) 17: 1070-1076.
29. Canchola AJ, Anton-Culver H, Bernstein L, Clarke CA, Henderson K,et al. (2012) Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control.
30. National Cancer Institute. General Information About Breast Cancer: Prognostic and Predictive Factors. NCI Website. Available: http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional#Reference1.16. Accessed 2013 Mar 5.